Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Long-term Diabetes Complications and Intensive Treatment Effects

Compared with routine care, early intensive multifactorial therapy shows little effect.... 

Advertisement

In an effort to determine the benefit of multifactorial treatment on microvascular complications among people with type 2 diabetes, Annelli Sandbaek, MD, PhD, and colleagues conducted a multicenter cluster randomized controlled trial at four centers in Denmark, the UK, and The Netherlands. Out of 3,057 people with diabetes detected by a screening process, only 2,861 were eligible for follow-ups. They were assigned to either the intensive treatment or routine care group.

The results from the four centers were collected using a fixed-effects meta-analysis. Of the patients who received intensive treatment, 22.7% showed any type of albuminuria, and patients who underwent routine care had 24.4%. Retinopathy was observed in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients. When it came to neuropathy, 4.9% was seen in intensive treatment patients, and 5.9% in routine care patients. However, in both groups the estimated glomerular filtration rate increased between baseline and follow-up; 4.31 mL/min was seen in the intensive treatment and 6.44 mL/min in the routine care groups.

According to the results of this study, researchers stated, "Compared with routine care, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was not associated with significant reductions in the frequency of microvascular events at five years."

Practice Pearls:
  • Albuminuria was 22.7% in the intensive group compared to 24% in the routine care group.
  • Retinopathy was present in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients
  • Neuropathy, 4.9%, was seen in intensive treatment patients, and 5.9% in routine care

Sandbaek A et al. Diabetes Care. 2014; doi: 10.2337/dc13-1544 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Past five issues: Diabetes Clinical Mastery Series Issue 219 | Issue 759 | Diabetes Clinical Mastery Series Issue 218 | GLP-1 Special Editions December 2014 | Issue 758 |

2014 Most Popular Articles:

Handbook of Diabetes, 4th Ed., Excerpt #20: Foot Problems in Diabetes
Posted November 29, 2014
New Guidelines for Doctors to Treat Diabetes
Posted December 12, 2014
Is Type 2 Diabetes an Inflammatory Disease?
Posted November 21, 2014
Why Are Up to 20% Type 2's Nonresponsive to Exercise?
Posted December 05, 2014
Handbook of Diabetes, 4th Ed., Excerpt #19: Macrovascular Disease in Diabetes
Posted November 23, 2014
Carbs Associated with Higher Diabetes and Heart Disease Risk Factor
Posted December 05, 2014
Any Pain Medication Said Effective When Treating Diabetic Nerve Pain
Posted November 21, 2014
Knowledge of Onset, Peak, and Duration of Action of Meds Prevents a Trip to the ER
Posted November 24, 2014
Link between Free Fatty Acids and Acute MI, Type 2 Diabetes
Posted November 21, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
How many of your prediabetic patients have delayed diabetes for more than 5 years with only lifestyle changes?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control